TELA
TELA Bio, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$1.29
+9.32%Price chart
Aug 18Aug 21Aug 26Aug 31Sep 3Sep 9Sep 14Sep 17
Key dataSep 17, 2026
Open$1.19
From 52W high−20.37%
Volume401589.00
Market cap$58.23M
P/E (TTM)—
P/S (TTM)0.7x
Div yield—
Key dataSep 17, 2026
Open
$1.19
From 52W high
−20.37%
Volume
401589.00
Market cap
$58.23M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.5x
P/E (TTM)
—
RSI (14)
81.3
MomentumView details →
1D Return
+9.32%
YTD Return
+3.81%
SummaryUpdated Jun 1, 2026
TELA Bio, Inc. (NASDAQ:TELA) is a commercial-stage medical technology company founded in 2012 and headquartered in Malvern, Pennsylvania. The company went public in November 2019 and specializes in developing and commercializing soft-tissue reconstruction solutions for hernia repair and plastic surgery applications. TELA Bio focuses on providing alternatives to traditional synthetic mesh products by offering reinforced tissue matrices derived from natural ovine (sheep) tissue combined with synthetic materials to optimize patient outcomes while preserving anatomical integrity.
Similar companies
Latest newsMore news →
Heather Getz was appointed principal financial officer of TELA Bio, Inc., effective August 31, 2026.17d agoTELA Bio announced a transition in its Chief Operating Officer and Chief Financial Officer roles.17d agoTELA Bio announced a strategic cost reduction initiative to reduce annual operating expenses by $17.0 million or 18%.17d ago